These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 34185336)

  • 81. COVID-19 infection in patients with haematological malignancies: A single-centre survey in the latest Omicron wave in China.
    Zhu X; Jiang Q; Lu J; Sun Y; Zhao X; Yang S; Tang F; Yu W; Zhao T; Liu X; Jia J; Duan W; Hu L; Wang J; Liu Y; Peng N; Dou X; Ma R; Fu Q; Wang H; Liu K; Huang X; Jiang H
    Br J Haematol; 2023 Jul; 202(1):31-39. PubMed ID: 37092433
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Therapy in Patients with Hematologic Malignancies, Seroconversion Rates, and SARS-CoV-2 Vaccination.
    Sriwijitalai W; Wiwanitkit V
    Oncologist; 2022 Nov; 27(11):e916. PubMed ID: 36018054
    [TBL] [Abstract][Full Text] [Related]  

  • 83. SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research.
    Guven DC; Sahin TK; Akın S; Uckun FM
    Oncologist; 2022 Nov; 27(11):e917-e918. PubMed ID: 36005823
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited.
    Ribas A; Sengupta R; Locke T; Zaidi SK; Campbell KM; Carethers JM; Jaffee EM; Wherry EJ; Soria JC; D'Souza G;
    Cancer Discov; 2021 Feb; 11(2):233-236. PubMed ID: 33355178
    [TBL] [Abstract][Full Text] [Related]  

  • 85. COVID-19 booster vaccines generate seroconversion in subset of patients with lymphoma/CLL: single institution experience.
    Mehta-Shah N; Bartlett NL; Kahl B; Watkins MP; Dubois A; Schmelzle G; Waqar S; Ballman C; Wan F; Farnsworth CW
    Leuk Lymphoma; 2022 Jul; 63(7):1723-1727. PubMed ID: 35225130
    [No Abstract]   [Full Text] [Related]  

  • 86. COVID-19 vaccine effectiveness in patients with hematologic malignancy.
    Shah DP; Shah PK; Thompson MA
    Transpl Infect Dis; 2022 Dec; 24(6):e13850. PubMed ID: 35584967
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Clinical characteristics and outcomes of COVID-19 infection in Chinese patients with hematologic malignancies in the Omicron era.
    Li X; Zhao A; Jiang H; Lu Y; Le J; Xie Y; Hu M; Zeng H; Zhao J; Zhou M; Zhou H; Chen L; Zhu W; Ouyang G; Qiu H; Jiang S; Guo Q; Qian W; Liang Y
    Hematology; 2023 Dec; 28(1):2288477. PubMed ID: 38038062
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report.
    Cuneo A; Rigolin GM; Coscia M; Quaresmini G; Scarfò L; Mauro FR; Motta M; Quaglia FM; Trentin L; Ferrario A; Laurenti L; Reda G; Ferrari A; Pietrasanta D; Sportoletti P; Re F; De Paoli L; Foglietta M; Giordano A; Marchetti M; Farina L; Del Poeta G; Varettoni M; Chiurazzi F; Marasca R; Malerba L; Ibatici A; Tisi MC; Stefoni V; Leone M; Baratè C; Olivieri J; Murru R; Gentile M; Sanna A; Gozzetti A; Gattei V; Gottardi D; Derenzini E; Levato L; Orsucci L; Penna G; Chiarenza A; Foà R
    Hematol Oncol; 2021 Oct; 39(4):570-574. PubMed ID: 34258787
    [No Abstract]   [Full Text] [Related]  

  • 89. Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy.
    Booth S; Curley HM; Varnai C; Arnold R; Lee LYW; Campton NA; Cook G; Purshouse K; Aries J; Innes A; Cook LB; Tomkins O; Oram HS; Tilby M; Kulasekararaj A; Wrench D; Dolly S; Newsom-Davies T; Pettengell R; Gault A; Moody S; Mittal S; Altohami M; Tillet T; Illingworth J; Mukherjee L; Apperly J; Ashcroft J; Rabin N; Carmichael J; Cazier JB; Kerr R; Middleton G; Collins GP; Palles C;
    Br J Haematol; 2022 Feb; 196(4):892-901. PubMed ID: 34761389
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Real-World Third COVID-19 Vaccine Dosing and Antibody Response in Patients With Hematologic Malignancies.
    Thompson MA; Hallmeyer S; Fitzpatrick VE; Liao Y; Mullane MP; Medlin SC; Copeland K; Weese JL
    J Patient Cent Res Rev; 2022; 9(3):149-157. PubMed ID: 35935520
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Managing and treating COVID-19 in patients with hematological malignancies: a narrative review and expert insights.
    Ng HJ; Alata MK; Nguyen QT; Huynh Duc Vinh P; Tan JY; Wong CL
    Clin Exp Med; 2024 Jun; 24(1):119. PubMed ID: 38833206
    [TBL] [Abstract][Full Text] [Related]  

  • 92. COVID-19 in Patients with Hematologic Malignancies: Clinical Manifestations, Persistence, and Immune Response.
    Gur I; Giladi A; Isenberg YN; Neuberger A; Stern A
    Acta Haematol; 2022; 145(3):297-309. PubMed ID: 35235928
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease.
    Ollila TA; Lu S; Masel R; Zayac A; Paiva K; Rogers RD; Olszewski AJ
    JAMA Oncol; 2021 Nov; 7(11):1714-1716. PubMed ID: 34379085
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Should we screen patients with hematologic malignancies for COVID-19?
    Rassy E; Khoury-Abboud RM; Ibrahim N; Assi T; Samra B; Hanna C; Karak FE; Ghosn M
    Hematol Oncol; 2020 Dec; 38(5):648-653. PubMed ID: 32779823
    [TBL] [Abstract][Full Text] [Related]  

  • 95. High mortality with High false negative rate: COVID-19 infection in patients with hematologic malignancies.
    Niu A; Ning B; Socola F; Safah H; Reynolds T; Ibrahim M; Safa F; Alfonso T; Luk A; Mushatt DM; Hu T; Saba NS
    Leuk Res; 2021 Jul; 106():106582. PubMed ID: 33933714
    [No Abstract]   [Full Text] [Related]  

  • 96. COVID-19 Vaccination Response and Its Practical Application in Patients With Chronic Lymphocytic Leukemia.
    Shadman M; Liu C; Eakle K; Hiew HJ; Biondo JML; Ghia P; Mato AR
    Hemasphere; 2023 Jan; 7(1):e811. PubMed ID: 36570695
    [TBL] [Abstract][Full Text] [Related]  

  • 97. COVID-19 in vaccinated versus unvaccinated hematologic malignancy patients.
    DeVoe C; Pandey S; Shariff D; Arora S; Henrich TJ; Yokoe DS; Langelier CR; Servellita V; Chiu C; Miller S; Babik JM; Chin-Hong P; Fung M
    Transpl Infect Dis; 2022 Dec; 24(6):e13835. PubMed ID: 35426225
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Immunogenicity and clinical efficacy of anti-SARS-CoV-2 vaccination in patients with hematological malignancies: Results of a prospective cohort study of 365 patients.
    Salvini M; Damonte C; Mortara L; Maggi F; Bruno A; Pellegrini G; Mora B; Brociner M; Ingrassia A; Mattarucchi R; Bianchi B; Sirocchi D; Agnoli S; Rumi E; Merli M; Fossati A; Bassi S; Bombelli R; Gallazzi M; Borsani O; Baj A; Franchi M; Grossi PA; Passamonti F
    Am J Hematol; 2022 Aug; 97(8):E321-E324. PubMed ID: 35702859
    [No Abstract]   [Full Text] [Related]  

  • 99. Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV.
    Zappasodi P; Cattaneo C; Valeria Ferretti V; Mina R; José María Ferreri A; Merli F; Oberti M; Krampera M; Romano A; Zerbi C; Ferrari J; Cavo M; Salvini M; Bertù L; Stefano Fracchiolla N; Marchesi F; Massaia M; Marasco V; Cairoli R; Maria Scattolin A; Maria Vannucchi A; Gambacorti-Passerini C; Musto P; Gherlinzoni F; Cuneo A; Pinto A; Trentin L; Bocchia M; Galimberti S; Coviello E; Chiara Tisi M; Morotti A; Falini B; Turrini M; Tafuri A; Billio A; Gentile M; Massimo Lemoli R; Venditti A; Giovanni Della Porta M; Lanza F; Rigacci L; Tosi P; Mohamed S; Corso A; Luppi M; Giuliani N; Busca A; Pagano L; Bruno R; Antonio Grossi P; Corradini P; Passamonti F; Arcaini L;
    Hematol Oncol; 2022 Dec; 40(5):846-856. PubMed ID: 35854643
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Benefit of repeated COVID-19 vaccination for patients with B-cell malignancies.
    Bacher U; Shumilov E; Pabst T
    Br J Haematol; 2023 Sep; 202(6):1081-1083. PubMed ID: 37519052
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.